Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. - Wikidata - awgldk - TriplyDB

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.

http://www.wikidata.org/entity/Q44548746

about

Self-monitoring and self-management of oral anticoagulation Assessing bleeding risk in patients taking anticoagulants Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Diagnosis and treatment of deep-vein thrombosis Anticoagulant treatment at a specialized outpatient anticoagulant therapy unit, a descriptive study Self-monitoring and self-management of oral anticoagulation Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation Recurrent venous thromboembolism: what is the risk and how to prevent it Predicting the risk of venous thromboembolism recurrence Review article: Venous thromboembolism after total joint replacement Chronic thromboembolic pulmonary hypertension: Medical treatment.Guidance for the treatment of deep vein thrombosis and pulmonary embolism Duration of anticoagulation for venous thromboembolic events Guidelines on oral anticoagulation with warfarin - fourth edition Pulmonary embolism in hospital practice.Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review.The role of ximelagatran in the treatment of venous thromboembolism.Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study.Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism.Thrombosis in small and medium-sized pulmonary arteries in Wegener's granulomatosis: a confocal laser scanning microscopy study.Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study.Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making Targeted gene sequencing identifies variants in the protein C and endothelial protein C receptor genes in patients with unprovoked venous thromboembolism.Evolving use of new oral anticoagulants for treatment of venous thromboembolism Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.Guidelines on oral anticoagulation (warfarin): third edition--2005 update.Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked Genetic determinants of response to warfarin during initial anticoagulation Optimal duration of anticoagulation after venous thromboembolism.Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials.Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial.

P2860

Q24235798-576F35AD-FBE4-465E-B368-2E1C15370774 Q24619070-8901EBA0-EE06-4B0D-8198-E5115065D27F Q24632951-C9E595E4-003A-47E2-8F42-74E1F4D21A8A Q24632982-8486AD6C-77D0-4F78-81E5-E565B8ED8C39 Q24633053-A0BC3FFE-4B42-4074-8216-FFE60B5CE8CD Q24673847-56DC3872-35F5-49D0-B2A6-1A0AF6ED3D6A Q25257138-A1F33A48-AE25-4AFC-9DAC-2D4528929332 Q26471166-66F85A80-BC6E-4D91-B23A-00C4E0AC7307 Q26749273-70C2BECA-A4A2-451A-BFB5-1BC8EBACDB7E Q26825608-EAC631A0-499B-4F33-B909-58960BCB9B4E Q26826847-D67C920A-585D-45FC-8A8A-834273B8C1A2 Q26865059-B0E42433-F1D6-4618-B380-7414E5F33309 Q27006824-28A4346D-B2CA-4132-9DC0-25B5BDC44611 Q27687768-2A6A96B0-5E2F-49BF-9B88-055657B50433 Q28078989-BFB9EE81-D32F-42F0-A80C-936309A6F1CA Q28081375-77B7A5CA-AABF-4F23-95C9-42F27123195C Q28240666-03D5A82F-A887-4530-AFD8-BFAEBE48F1C7 Q30476617-63BF4693-7E67-4359-BA48-D98DE7FB4731 Q33348847-0E943CB3-0C66-4366-8B3C-0B8A94A9A3CC Q33369274-84902247-D0F2-4684-AF8A-C07786722436 Q33685299-20A187FF-2870-4848-99EF-A55D31B3D0F0 Q33755738-97004235-B7F8-4899-AA37-D96B41FA2D31 Q33790855-7C4D1ED7-1A83-4C10-B9C4-E463ADC6245B Q33795571-76B7E3CD-5913-4BDE-9305-E81D5FB8EDF2 Q33821311-B921A5A9-D795-4D8E-B8C8-C4152A0A4777 Q33910755-8FB93AA6-31F2-4D45-BAA9-FD01DFB1BA0F Q33949571-0B5AB6A0-3E60-4EC2-8172-82A120FDD367 Q33973390-409667BD-AEFB-4AC3-BCB2-EF6785E196BA Q34047821-B45B626F-1C8A-40AC-95F5-028C8EDA0BD1 Q34146486-EA10C717-07C1-455B-A821-7D9FE783E5E8 Q34200483-F025FA4A-13D7-4C4D-8761-771266B52B49 Q34252907-D74D3794-3836-48DF-A805-DD4F58609688 Q34362277-4AAED7F3-E51D-484E-BDD3-B49B3EE6472E Q34437785-B20A2F37-BAD6-4EAB-BB65-26D77B884C0A Q34484090-2A70C397-0D56-4D71-B32D-841FC4FC9235 Q34623435-57920932-27AE-4965-A6E8-E9CA1C71A560 Q34759038-AD5A0E4B-6AF7-4093-8B49-7C63B1EA8024 Q34781477-1EC48084-FE75-44A7-8E2B-12F09C826D3F Q34787240-3AAF75BE-BA32-45C8-BFD6-87066614B2A1 Q34926806-FCFC3508-6F73-4722-A5EA-80CA8216D646

P2860

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.

http://www.wikidata.org/entity/Q44548746

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Comparison of low-intensity wa ...... urrent venous thromboembolism.

@en

Comparison of low-intensity wa ...... urrent venous thromboembolism.

@nl

type

label

Comparison of low-intensity wa ...... urrent venous thromboembolism.

@en

Comparison of low-intensity wa ...... urrent venous thromboembolism.

@nl

prefLabel

Comparison of low-intensity wa ...... urrent venous thromboembolism.

@en

Comparison of low-intensity wa ...... urrent venous thromboembolism.

@nl

P1433

Q44548746-3FED7446-7A08-4BF9-83B3-6AE20A52F2C4

P1476

Q44548746-5B03CA74-4650-4C7A-85C1-81F2EED2335A

P2093

Q44548746-0073C2B1-CED5-46FA-8581-5B82269F171B

Q44548746-090ADD0A-4FB4-41B5-B2C2-85EB553D83AB

Q44548746-0EDAF7D8-A040-4569-9ADB-FBDBFADF7207

Q44548746-15DFB275-2785-46F5-9644-CA4C922199BA

Q44548746-1770F1CC-C59A-44E4-898D-99918E819A3C

Q44548746-1908EB95-DB4E-4712-8868-F0A162ED28C8

Q44548746-62203563-C216-4D8B-B5EA-7E33410310ED

Q44548746-9454698C-E4DC-48CF-9F5B-95FF46012D05

Q44548746-99C188EF-8248-4F37-99DA-9FE57C8D9124

Q44548746-9DDF5E9D-22D7-4D7F-829F-45ED1CDCCD03

P304

Q44548746-6826B21A-C9C7-40F0-BBF2-39E2ECDDD04A

P31

Q44548746-23B24C4F-5C74-41F8-AA6A-D7A5742C323D

P356

Q44548746-99E50B32-2F5F-4A64-8B02-ED0D5E2ADD58

P407

Q44548746-8CA6FB51-AD41-4E2D-8D0D-A8AFFB69C410

P433

Q44548746-A834D13E-1B70-4573-A65C-ABFD1B703459

P478

Q44548746-F6ACAC84-4A13-45EB-944C-253296573FA8

P577

Q44548746-457AA7DE-3B70-4C8F-ACC6-B54757F42201

P698

Q44548746-35C2FA7E-7B9B-4256-AE13-21837700AE0B

P356

P1433

The New England Journal of Medicine

P1476

Comparison of low-intensity wa ...... urrent venous thromboembolism.

@en

P2093

Alexander G Turpie

http://www.w3.org/2001/XMLSchema#string

Betsy MacKinnon

http://www.w3.org/2001/XMLSchema#string

Christine Demers

http://www.w3.org/2001/XMLSchema#string

Clive Kearon

http://www.w3.org/2001/XMLSchema#string

David R Anderson

http://www.w3.org/2001/XMLSchema#string

Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators

http://www.w3.org/2001/XMLSchema#string

Jeannine Kassis

http://www.w3.org/2001/XMLSchema#string

Jeffrey I Weitz

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Ginsberg

http://www.w3.org/2001/XMLSchema#string

Jim A Julian

http://www.w3.org/2001/XMLSchema#string

P304

631-639

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA035422

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

349

http://www.w3.org/2001/XMLSchema#string

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12917299

http://www.w3.org/2001/XMLSchema#string